CChoy M, et al. - Researchers aspired to determine the factors that predict colectomy in hospitalized patients who received infliximab for acute severe ulcerative colitis (ASUC) at 7 Australian centers (April 2014–May 2015). In contrast with standard infliximab (SI), a numerically higher colectomy rate was discovered in those treated with accelerated infliximab (AI). Nevertheless, those treated with AI presented with a more severe biochemical disease. The prominent predictors of treatment response for ASUC appeared to be the baseline Mayo Endoscopic Score and the CRP/albumin ratio following infliximab salvage. It aided in detecting subjects at high risk of colectomy.